Quoin Pharmaceuticals (QNRX) investor relations material

Executive summary

• Focused on developing therapies for rare and orphan diseases, with QRX003 in late-stage clinical trials for Netherton Syndrome and expansion into other indications and geographies.

• Positive six-month clinical data for pediatric Netherton Syndrome and Peeling Skin Syndrome studies, showing significant improvement and no adverse events.

• FDA cleared a second pivotal study of QRX003 for Netherton Syndrome; recruitment expected to conclude by end of Q1 2026.

• Orphan Drug Designation granted by EMA and Rare Pediatric Disease Designation awarded by FDA for QRX003.

• No commercialized products or revenue to date; continued reliance on external financing for operations.

Financial highlights

• Net loss of $3.7 million for Q2 2025, up from $2.0 million in Q2 2024; net loss of $7.5 million for the six months ended June 30, 2025, up from $4.3 million year-over-year.

• Operating expenses rose to $3.8 million in Q2 2025 from $2.1 million in Q2 2024, driven by higher R&D and G&A costs.

• Cash, cash equivalents, and marketable securities totaled $7.8 million as of June 30, 2025, expected to fund operations into Q1 2026.

• Accumulated deficit reached $62.7 million as of June 30, 2025.

• R&D expenses rose to $2.1 million in Q2 2025 from $0.6 million in Q2 2024.

Outlook and guidance

• Management does not expect revenue from product sales for several years; additional financing is required to fund ongoing operations and development.

• NDA filing for QRX003 anticipated in 2026 following completion of pivotal study recruitment.

• Capital is expected to support operations into the first quarter of 2026.

• Plans to complete QRX003 clinical trials and seek marketing approval, while expanding pipeline through partnerships and licensing.

• Additional studies in other rare skin disease indications planned in coming months.